Extract
心血管和呼吸系统疾病是全球死亡的主要贡献者[1]。虽然低肺功能是早期死亡的危险因素,如高血压和高胆固醇血症[2],初级保健中肺功能的评估不如血压或胆固醇测量值优先考虑[3]。此外,公共卫生当局对吸烟以外的主要健康挑战仍保持沉默,从而从出生到老年的良好肺功能。现在越来越明显,儿童时期的低肺功能可能会影响整个寿命的一般健康[4-8]。因此,它似乎有可能在人口范围内改善肺功能可能与较低的发病率和死亡率相关。因此,我们测试了超正态肺功能与较低的发病率和死亡率相关的假设。
抽象的
超正态肺功能与较少的心血管和呼吸事件相关,并且生存受益独立于主要危险因素https://bit.ly/371l3ut
脚注
Author contributions: Y. Çolak and S. Afzal had full access to all the data in the study and had final responsibility for the decision to submit for publication. Y. Çolak, B.G. Nordestgaard, J. Vestbo, P. Lange and S. Afzal contributed to the study concept and design. Y. Çolak, B.G. Nordestgaard, J. Vestbo, P. Lange and S. Afzal collected, analysed, or interpreted the data. Y. Çolak wrote the draft manuscript and performed the statistical analyses. Y. Çolak, B.G. Nordestgaard, J. Vestbo, P. Lange and S. Afzal revised the manuscript for important intellectual content. B.G. Nordestgaard obtained funding. B.G. Nordestgaard provided administrative, technical, or material support. S. Afzal supervised the study.
利益冲突:B.G.Nordestgaard没有什么可以披露的。
利益冲突:J.Vesbo报告了Glaxosmithkline,Chiesi Pharmaceuticals,Boehringer,Astazenec,Astazeneca和Bioxyn的顾问,戏外所讲座的个人费用,Chiesi Pharmaceuticals,Novartis,Astrazeneca和Boehringer Ingelheim的个人费用;而作者的配偶是葛兰素,阿斯塔州科和飞行员的前雇员。
兴趣冲突:P. Lange报道Almirall,Boehringer Ingelheim和GSK的赠款和个人费用,从Astrazeneca,Novartis,Nycomed,Pufizer和Mundipharma的个人费用,外部提交的工作之外。
Conflict of interest: S. Afzal has nothing to disclose.
利益冲突:Y.Çolak报告Boehringer Ingelheim,Astrazeneca和Sanofi Genzyme的个人费用在提交的工作之外。
Support statement: This study was funded by the Lundbeck Foundation. The funder had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Y. Çolak and S. Afzal had full access to all data in the study and had final responsibility for the decision to submit for publication. Funding information for this article has been deposited with theCrossref Funder Registry.
- 已收到September 3, 2020.
- AcceptedNovember 13, 2020.
- 复制right ©ERS 2021